Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-102: HS-20093 Combinations in Metastatic Colorectal Cancer
NCT06825624Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in colorectal cancer (metastatic) (mCRC) (5 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2024; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06825624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825624.